Systems analysis of the prostate transcriptome in African-American men compared with European-American men

Pharmacogenomics

Volumn 17, Issue 10, 2016, Pages 1129-1143

  Hardiman, Gary ^a   Savage, Stephen J ^c,d   Hazard, E Starr ^a,b   Wilson, Robert C ^a   Courtney, Sean M ^a   Smith, Michael T ^a   Hollis, Bruce W ^a   Halbert, Chanita Hughes ^a,d   Gattoni Celli, Sebastiano ^a,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c Ralph H Johnson VA Medical Center ^*  (United States)

^d RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

African American; health disparities; prostate; RNA seq; transcription; Vitamin D

Indexed keywords

COLECALCIFEROL; GROWTH DIFFERENTIATION FACTOR 15; PLACEBO; TRANSCRIPTOME; VITAMIN D;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER MORTALITY; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EUROPEAN AMERICAN; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLEASON SCORE; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INFLAMMATION; MALE; MIDDLE AGED; OPEN STUDY; PREVALENCE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SYSTEM ANALYSIS; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; CAUCASIAN; COHORT ANALYSIS; COMPARATIVE STUDY; DIETARY SUPPLEMENT; DRUG EFFECTS; GENETICS; PHYSIOLOGY; PROSPECTIVE STUDY; PROSTATE; PROSTATIC NEOPLASMS;

AFRICAN AMERICANS; AGED; CHOLECALCIFEROL; COHORT STUDIES; DIETARY SUPPLEMENTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; SYSTEMS ANALYSIS; TRANSCRIPTOME;

EID: 84979582168     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs-2016-0025     Document Type: Article

References (46)

1. Freedland SJ, Amling CL, Dorey F et al. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology 60(4), 670-674 (2002).
2. Freedland SJ, Sutter ME, Naitoh J, Dorey F, Csathy GS, Aronson WJ. Clinical characteristics in black and white men with prostate cancer in an equal access medical center. Urology 55(3), 387-390 (2000).
3. Esvelt RP, Schnoes HK, Deluca HF. Vitamin D3 from rat skins irradiated in vitro with ultraviolet light. Arch. Biochem. Biophys. 188(2), 282-286 (1978).
4. Maclaughlin JA, Holick MF. Mediation of cutaneous vitamin D3 synthesis by UV radiation. In: Biochemistry and Physiology of the Skin. Goldsmith LA (Ed.). Oxford University Press, Oxford, UK (1983).
5. Matsuoka LY, Wortsman J, Haddad JG, Kolm P, Hollis BW. Racial pigmentation and the cutaneous synthesis of vitamin D. Arch. Dermatol. 127(4), 536-538 (1991).
6. Clemens TL, Adams JS, Henderson SL, Holick MF. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet (London, England) 1(8263), 74-76 (1982).
7. Vieth R, Chan PCR, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level (LOAEL). Am. J. Clin. Nutr. 73(2), 288-294 (2001).
8. Garrett-Mayer E, Wagner CL, Hollis BW, Kindy MS, Gattoni-Celli S. Vitamin D3 supplementation (4000 IU/d for 1 y) eliminates differences in circulating 25-hydroxyvitamin D between African American and white men. Am. J. Clin. Nutr. 96(2), 332-336 (2012).
9. Hollis BW, Marshall DT, Savage SJ, Garrett-Mayer E, Kindy MS, Gattoni-Celli S. Vitamin D3 supplementation, low-risk prostate cancer, and health disparities. J. Steroid Biochem. Mol. Biol. 136 233-237 (2013).
10. Halliday TM, Peterson NJ, Thomas JJ, Kleppinger K, Hollis BW, Larson-Meyer DE. Vitamin D status relative to diet, lifestyle, injury, and illness in college athletes. Med. Sci. Sports Exercise 43(2), 335-343 (2011).
11. Feldman D, Pike JW, Adams JS. In: Vitamin D (3rd Edition). Academic Press San Diego ix, CA, USA (2011).
12. Miller GJ, Stapleton GE, Ferrara JA et al. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25- dihydroxyvitamin D3. Cancer Res. 52(3), 515-520 (1992).
13. Hendrickson WK, Flavin R, Kasperzyk JL et al. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J. Clin. Oncol. 29(17), 2378-2385 (2011).
14. Ellfolk M, Norlin M, Gyllensten K, Wikvall K. Regulation of human vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells. Mol. Pharmacol. 75(6), 1392-1399 (2009).
15. Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol. Biomarkers Prev. 7(5), 391-395 (1998).
16. Deeb KK, Luo W, Karpf AR et al. Differential vitamin D 24-hydroxylase/CYP24A1 gene promoter methylation in endothelium from benign and malignant human prostate. Epigenetics 6(8), 994-1000 (2011).
17. Barreto AM, Schwartz GG, Woodruff R, Cramer SD. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol. Biomarkers Prev. 9(3), 265-270 (2000).
18. Chen TC, Wang L, Whitlatch LW, Flanagan JN, Holick MF. Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J. Cell. Biochem. 88(2), 315-322 (2003).
19. Krishnan AV, Feldman D. Vitamin D and prostate cancer (Chapter 86). In: Vitamin D (Third Edition). Adams DFWPS (Ed.). Academic Press, CA, USA, 1675-1709 (2011).
20. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res. 65(17), 7917-7925 (2005).
21. Cohen BL, Gomez P, Omori Y et al. Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence. Int. J. Cancer 119(5), 1082-1087 (2006).
22. Bao BY, Yao J, Lee YF. 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 27(9), 1883-1893 (2006).
23. Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br. J. Cancer 93(9), 1019-1023 (2005).
24. Wang TT, Tavera-Mendoza LE, Laperriere D et al. Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol. Endocrinol. 19(11), 2685-2695 (2005).
25. Ramagopalan SV, Heger A, Berlanga AJ et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res. 20(10), 1352-1360 (2010).
26. Gennari L, Merlotti D, De Paola V, Martini G, Nuti R. Update on the pharmacogenetics of the vitamin D receptor and osteoporosis. Pharmacogenomics 10(3), 417-433 (2009).
27. Schwartz GG. Vitamin D and the epidemiology of prostate cancer. Sem. Dialysis 18(4), 276-289 (2005).
28. Nesby-O'Dell S, Scanlon KS, Cogswell ME et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. Am. J. Clin. Nutr. 76(1), 187-192 (2002).
29. Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am. J. Clin. Nutr. 88(6), 1519-1527 (2008).
30. Chandler PD, Giovannucci EL, Scott JB et al. Null association between vitamin D and PSA levels among black men in a vitamin D supplementation trial. Cancer Epidemiol. Biomarkers Prev. 23(9), 1944-1947 (2014).
31. Kristal AR, Till C, Song X et al. Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol. Biomarkers Prev. 23(8), 1494-1504 (2014).
32. Schenk JM, Till CA, Tangen CM et al. Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol. Biomarkers Prev. 23(8), 1484-1493 (2014).
33. Marshall DT, Savage SJ, Garrett-Mayer E et al. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J. Clin. Endocrinol. Metab. 97(7), 2315-2324 (2012).
34. Trapnell C, Roberts A, Goff L et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7(3), 562-578 (2012).
35. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-Seq data with DESeq2. Genome Biol. 15(12), 550 (2014).
36. Kozak I, Sasik R, Freeman WR et al. A degenerative retinal process in HIV-associated non-infectious retinopathy. PLoS ONE 8(9), e74712 (2013).
37. Paolini P, Pick D, Lapira J et al. Developmental and extracellular matrix-remodeling processes in rosiglitazoneexposed neonatal rat cardiomyocytes. Pharmacogenomics 15(6), 759-774 (2014).
38. Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 37(Web Server Issue), W305-W311 (2009).
39. Hulsen T, De Vlieg J, Alkema W. BioVenn - a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams. BMC Genom. 9, 488 (2008).
40. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 11(10), R106 (2010).
41. Anders S, Mccarthy DJ, Chen Y et al. Count-based differential expression analysis of RNA sequencing data using R and Bioconductor. Nat Protoc. 8(9), 1765-1786 (2013).
42. Zimmers TA, Jin X, Hsiao EC, Mcgrath SA, Esquela AF, Koniaris LG. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock (GA, USA) 23(6), 543-548 (2005).
43. Lambert JR, Whitson RJ, Iczkowski KA et al. Reduced expression of GDF-15 is associated with atrophic inflammatory lesions of the prostate. Prostate 75(3), 255-265 (2015).
44. Wallace TA, Prueitt RL, Yi M et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 68(3), 927-936 (2008).
45. Murphy AB, Nyame Y, Martin IK et al. Vitamin D deficiency predicts prostate biopsy outcomes. Clin. Cancer Res. 20(9), 2289-2299 (2014).
46. Swami S, Krishnan AV, Wang JY et al. Dietary vitamin D(3) and 1,25-dihydroxyvitamin D(3) (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology 153(6), 2576-2587 (2012).